steven johnson syndrome glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases Stevens-Johnson Syndrome | Consultant360

None of us got dark after spending an afternoon out in the sun swimming, walking on the beach, and kayakking

Parakh S, Atkin JD

The body has adapted to the medication

Typical subcutaneous dosing ranges from 1-3 mg daily or 3-5 times per week, often cycled in 8-12 week protocols with 4-week breaks to prevent receptor downregulation or copper accumulation

Therefore, DON treatment can not only reduce the self-renewal potential and metastatic ability of pancreatic ductal adenocarcinoma (PDAC) tumor cells but also lead to extensive remodeling of the tumor extracellular matrix (ECM), promoting the infiltration and activation of CD8 + T cells (Sharma et al., 2020)